# E-DRUG: Dipyrone in Sweden **URL:** \ **Category:** e-drug\ **Created:** [October 6, 1997, 3:19am UTC](https://talk.edrugplus.org/t/e-drug-dipyrone-in-sweden/1481 "1997-10-06T03:19:36Z")\ **Posts on this page:** 1\ **Page:** 1
**Author:** ![lo1](https://avatars.discourse-cdn.com/v4/letter/l/e68b1a/32.png) [@lo1](https://talk.edrugplus.org/u/lo1)\ **Post date:** [October 6, 1997, 3:19am UTC](https://talk.edrugplus.org/t/e-drug-dipyrone-in-sweden/1481/1 "1997-10-06T03:19:36Z")
------------------------------------------- The pivotal person in this re-approval was Bengt Wiholm, head of the adverse reactions division of the Swedish drug agency (Medical Products Agency) in Uppsala who was at the time a member of the IAAAS team ("Boston trial"), and has always staunchly defended the point of view and the statistical data of this trial. In retrospect - and in view of the commercial goals of the IAAAS - one could have some doubts whether it was wise decision for a civil servant to play such an active role, but that is for others to judge. At the time Barbro Westerholm still maintained that her own data mirrored the truth.          Bengt Wiholm is therefore probably in the best position to defend Hoechst's point of view and explain why the MPA approved dipyrone again.          Leo Offerhaus MD PhD Koedijklaan 1a 1406 KW Bussum The Netherlands Tel 0031-35-6923288 Fax 0031-35-6923290 E-mail: LO@EURONET.NL, CompuServe 71530,15 Eur J Clin Pharmacol ONLY: POB 75552, 1070 AN Amsterdam ------------------------------------------- I would be fascinated to know the reasons for Sweden reapproving dipyrone. It is registered in South Africa and widely used in combination with hyoscine butyl bromide. Many clinicians feel that the SA Regulatory Authority (MCC) would have withdrawn dipyrone if the evidence against it was conclusive. Colleagues who have reviewed the literature also feel that there is not enough conclusive evidence against dipyrone, and the risk of serious adverse effects is not great. The use of a NSAID related agent in combination with a belladonna alkaloid (theSA product) is not rational, particularly where the indication is antispasmodic. However, a balanced review of the data for and against its use will ultimately decide the fate of dipyrone. Can anyone, particularly Sweden comment from this aspect. With thanks        Leesette Turner Moderator, INDICES South Africa Email: hamis@iafrica.com Note from the moderator: ------------------------ I am copying the above messages and the original to Dr. Beje Wiholm of Swedish with a request for feed- back. Thanks. Syed Rizwanuddin Ahmad Email: srahmad@essential.org -- Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'. Mail administrative requests to `majordomo@usa.healthnet.org'. For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.